Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

68.72 -0.01 (-0.01%)
Streaming Delayed Price Updated: 10:12 AM EDT, Jul 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 231,464
Open 68.61
Bid (Size) 68.66 (1)
Ask (Size) 68.77 (1)
Prev. Close 68.73
Today's Range 68.18 - 69.01
52wk Range 53.56 - 83.95
Shares Outstanding 222,430,635
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Q1 Immuno-Oncology Earnings Review: First Prize Goes to Natera (NASDAQ:NTRA)
Let’s dig into the relative performance of Natera (NASDAQ:NTRA) and its peers as we unravel the now-completed Q1 immuno-oncology earnings season. 
Via StockStory
Topics Artificial Intelligence
Top S&P500 movers in Friday's session
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday. 
Via Chartmill

Performance

YTD
-1.2%
-1.2%
1 Month
+5.2%
+5.2%
3 Month
+12.8%
+12.8%
6 Month
-0.5%
-0.5%
1 Year
+12.9%
+12.9%

More News

Read More
Incyte CEO Shake-Up Sparks M&A Buzz As RBC Analyst Highlights Meury’s Track Record: Retail Is All In
Via Stocktwits
Topics Intellectual Property
Uncover the latest developments among S&P500 stocks in today's session.
Via Chartmill
Where Incyte Stands With Analysts
Via Benzinga
Thursday's session: top gainers and losers in the S&P500 index
Via Chartmill
Why New Incyte CEO Bill Meury Is Stoking Investors' M&A Hopes
Via Investor's Business Daily
Get insights into the top movers in the S&P500 index of Thursday's pre-market session.
Via Chartmill
Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire
From Incyte
Via Business Wire
Update on FDA Review of Ruxolitinib Cream (Opzelura®) for Children Ages 2-11 with Atopic Dermatitis
From Incyte
Via Business Wire
INCYTE CORP (NASDAQ:INCY) – A Biopharmaceutical Stock with Undervalued Potential
Via Chartmill
3 Low-Volatility Stocks with Questionable Fundamentals
Via StockStory
Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma
From Incyte
Via Business Wire
3 Unpopular Stocks in Hot Water
Via StockStory
Stay updated with the S&P500 stocks that are on the move in today's pre-market session.
Via Chartmill
Incyte's Experimental Therapy Shows Platelet Normalization And Safety In Rare Blood Cancer Trials Across Doses
Via Benzinga
Why Incyte Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Retail Investors Flock To Incyte As Drug Data, Qiagen Deal Fuel Optimism
Via Stocktwits
QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)
From QIAGEN N.V.
Via Business Wire
Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025
From Incyte
Via Business Wire
Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet
From Incyte
Via Business Wire
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025
From Incyte
Via Business Wire
INCYTE CORP (NASDAQ:INCY) – A Potential Undervalued Opportunity in Biotech
Via Chartmill
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire

Frequently Asked Questions

Is Incyte Corporation - Common Stock publicly traded?
Yes, Incyte Corporation - Common Stock is publicly traded.
What exchange does Incyte Corporation - Common Stock trade on?
Incyte Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Incyte Corporation - Common Stock?
The ticker symbol for Incyte Corporation - Common Stock is INCY on the Nasdaq Stock Market
What is the current price of Incyte Corporation - Common Stock?
The current price of Incyte Corporation - Common Stock is 68.72
When was Incyte Corporation - Common Stock last traded?
The last trade of Incyte Corporation - Common Stock was at 07/02/25 10:12 AM ET
What is the market capitalization of Incyte Corporation - Common Stock?
The market capitalization of Incyte Corporation - Common Stock is 15.29B
How many shares of Incyte Corporation - Common Stock are outstanding?
Incyte Corporation - Common Stock has 15B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.